Plain-English translation of NCT06758401 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combined with works better than alone for treating advanced lung cancer. is an immunotherapy drug that helps your immune system fight cancer. Researchers want to see if adding this new medication improves outcomes for patients whose cancer cells have high levels of a protein called PD-L1.
alone helps some patients with advanced lung cancer, but not everyone responds well enough. This study is testing whether adding this new medication can help more patients and help them live longer.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive by IV infusion every 6 weeks. Half of participants will also receive by IV infusion every 2 weeks. You will have regular clinic visits so the study team can monitor how you are doing and check for side effects. You can continue for up to about 2 years, while the additional medication continues as long as it appears to be helping your cancer.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States